340 related articles for article (PubMed ID: 31996670)
1. Modeling medulloblastoma in vivo and with human cerebellar organoids.
Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
[TBL] [Abstract][Full Text] [Related]
2. Joint binding of OTX2 and MYC in promotor regions is associated with high gene expression in medulloblastoma.
Bunt J; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
PLoS One; 2011; 6(10):e26058. PubMed ID: 22016811
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
4. Chromatin accessibility mapping identifies mediators of basal transcription and retinoid-induced repression of OTX2 in medulloblastoma.
Wortham M; Guo C; Zhang M; Song L; Lee BK; Iyer VR; Furey TS; Crawford GE; Yan H; He Y
PLoS One; 2014; 9(9):e107156. PubMed ID: 25198066
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma.
Stromecki M; Tatari N; Morrison LC; Kaur R; Zagozewski J; Palidwor G; Ramaswamy V; Skowron P; Wölfl M; Milde T; Del Bigio MR; Taylor MD; Werbowetski-Ogilvie TE
Mol Oncol; 2018 Apr; 12(4):495-513. PubMed ID: 29377567
[TBL] [Abstract][Full Text] [Related]
6. Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines.
Bunt J; de Haas TG; Hasselt NE; Zwijnenburg DA; Koster J; Versteeg R; Kool M
Mol Cancer Res; 2010 Oct; 8(10):1344-57. PubMed ID: 21047732
[TBL] [Abstract][Full Text] [Related]
7. The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma.
Qin N; Paisana E; Picard D; Leprivier G; Langini M; Custódia C; Cascão R; Conrad C; Peitzsch M; Stefanski A; Stühler K; Fischer U; Faria CC; Dietrich S; Reifenberger G; Remke M
J Neurooncol; 2023 Nov; 165(2):329-342. PubMed ID: 37976029
[TBL] [Abstract][Full Text] [Related]
8. OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma.
Boulay G; Awad ME; Riggi N; Archer TC; Iyer S; Boonseng WE; Rossetti NE; Naigles B; Rengarajan S; Volorio A; Kim JC; Mesirov JP; Tamayo P; Pomeroy SL; Aryee MJ; Rivera MN
Cancer Discov; 2017 Mar; 7(3):288-301. PubMed ID: 28213356
[TBL] [Abstract][Full Text] [Related]
9.
Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
[TBL] [Abstract][Full Text] [Related]
10. Targeting the enhancer of zeste homologue 2 in medulloblastoma.
Alimova I; Venkataraman S; Harris P; Marquez VE; Northcott PA; Dubuc A; Taylor MD; Foreman NK; Vibhakar R
Int J Cancer; 2012 Oct; 131(8):1800-9. PubMed ID: 22287205
[TBL] [Abstract][Full Text] [Related]
11. PTCH1-mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis.
van Essen MJ; Apsley EJ; Riepsaame J; Xu R; Northcott PA; Cowley SA; Jacob J; Becker EBE
Dis Model Mech; 2024 Feb; 17(2):. PubMed ID: 38411252
[TBL] [Abstract][Full Text] [Related]
12. MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation.
Liu H; Sun Q; Sun Y; Zhang J; Yuan H; Pang S; Qi X; Wang H; Zhang M; Zhang H; Yu C; Gu C
Mol Cancer Res; 2017 Sep; 15(9):1275-1286. PubMed ID: 28536141
[TBL] [Abstract][Full Text] [Related]
13. The
Ampudia-Mesias E; Cameron CS; Yoo E; Kelly M; Anderson SM; Manning R; Abrahante Lloréns JE; Moertel CL; Yim H; Odde DJ; Saydam N; Saydam O
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674001
[TBL] [Abstract][Full Text] [Related]
14. OTX2 exhibits cell-context-dependent effects on cellular and molecular properties of human embryonic neural precursors and medulloblastoma cells.
Kaur R; Aiken C; Morrison LC; Rao R; Del Bigio MR; Rampalli S; Werbowetski-Ogilvie T
Dis Model Mech; 2015 Oct; 8(10):1295-309. PubMed ID: 26398939
[TBL] [Abstract][Full Text] [Related]
15. An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate.
Zagozewski J; Shahriary GM; Morrison LC; Saulnier O; Stromecki M; Fresnoza A; Palidwor G; Porter CJ; Forget A; Ayrault O; Hawkins C; Chan JA; Vladoiu MC; Sundaresan L; Arsenio J; Taylor MD; Ramaswamy V; Werbowetski-Ogilvie TE
Nat Commun; 2020 Jul; 11(1):3627. PubMed ID: 32686664
[TBL] [Abstract][Full Text] [Related]
16. SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development.
Shi X; Wang Q; Gu J; Xuan Z; Wu JI
Oncogene; 2016 Nov; 35(44):5746-5758. PubMed ID: 27065321
[TBL] [Abstract][Full Text] [Related]
17. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
18. MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice.
Göbel C; Godbole S; Schoof M; Holdhof D; Kresbach C; Loose C; Neumann J; Schüller U
Acta Neuropathol Commun; 2023 Nov; 11(1):174. PubMed ID: 37919824
[TBL] [Abstract][Full Text] [Related]
19. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
